See analyst estimates and all valuation multiples for Chemicals
| Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| $232B | 7.0x | 17.8x | |
| $101B | 4.3x | 22.1x | |
| $78.8B | 5.0x | 21.6x | |
| $75.2B | 6.3x | 14.9x | |
| $66.4B | 0.9x | 7.5x | |
| $47.4B | 2.7x | 7.0x | |
| $46.5B | 1.2x | 8.9x | |
| $45.9B | 3.2x | 16.6x | |
| $45.0B | 21.3x | 469.2x | |
| $40.9B | 1.6x | 7.4x | |
| $37.3B | 1.4x | 8.4x | |
| $37.3B | 0.9x | 7.5x | |
| $33.5B | 1.0x | 9.5x | |
| $33.4B | 2.7x | 10.4x | |
| $32.8B | 7.4x | 20.0x | |
| $31.1B | 2.1x | 12.5x | |
| $30.8B | 2.0x | 10.7x | |
| $29.1B | 0.8x | 7.3x | |
| $28.1B | 2.5x | 13.0x | |
| $25.5B | 6.4x | 35.7x | |
| $24.8B | 0.7x | 5.7x | |
| $23.3B | 3.9x | 9.8x | |
| $20.2B | 3.7x | 10.8x | |
| $19.8B | 2.2x | 9.6x | |
| $19.7B | 1.7x | 10.8x | |
| $18.4B | 3.2x | 15.5x | |
| $18.0B | 0.5x | 2.2x | |
| $17.8B | 1.8x | 8.0x | |
| $17.6B | 4.1x | 15.9x | |
| $16.3B | 2.2x | 14.4x | |
| $15.9B | 6.4x | 22.1x | |
| $15.8B | 1.3x | 9.4x | |
| $15.5B | 1.0x | 12.6x | |
| $15.5B | 3.1x | 11.2x | |
| $15.2B | 2.5x | 6.6x | |
| $14.1B | 0.8x | 6.0x | |
| $13.6B | 1.4x | 7.6x | |
| $13.3B | 1.1x | 6.3x | |
| $12.8B | 0.7x | 7.6x | |
| $12.6B | 2.7x | 8.2x | |
| $12.2B | 0.8x | 5.5x | |
| $11.2B | 2.1x | 10.3x | |
| $10.1B | 1.4x | 5.8x | |
| $9.8B | 4.5x | 10.6x | |
| $9.4B | 3.2x | 8.6x | |
| $9.3B | 1.7x | 14.0x | |
| $9.0B | 1.2x | 5.7x | |
| $8.7B | 0.8x | 5.1x | |
| $8.3B | 2.0x | 9.2x | |
| $7.1B | 0.5x | 2.7x | |
| $6.4B | 3.0x | 9.1x | |
| $6.1B | 2.4x | -896.4x | |
| $6.0B | 6.3x | 23.0x | |
| $5.7B | 1.4x | 9.4x | |
| $5.5B | 1.2x | 9.5x | |
| $5.4B | 1.1x | 6.6x | |
| $5.3B | 0.7x | 7.7x | |
| $5.2B | 0.6x | 7.2x | |
| $5.0B | 0.9x | 4.3x | |
| $4.7B | 2.5x | 10.1x | |
| $4.5B | 1.7x | 13.4x | |
| $4.4B | 5.8x | 19.8x | |
| $4.4B | 0.7x | 5.2x | |
| $4.1B | 0.4x | 13.4x | |
| $4.0B | n/a | n/a | |
| $3.7B | 1.7x | 8.0x | |
| $3.5B | 1.1x | 5.4x | |
| $3.4B | 12.4x | 47.2x | |
| $3.3B | n/a | n/a | |
| $3.3B | 0.8x | 15.3x | |
| $3.3B | 7.1x | 23.0x | |
| $3.2B | 5.2x | 29.5x | |
| $3.0B | 0.7x | 4.7x | |
| $2.8B | 0.8x | -69.4x | |
| $2.4B | n/a | n/a | |
| $2.0B | 2.2x | 11.6x | |
| $2.0B | 0.6x | 5.2x | |
| $2.0B | 2.7x | 10.4x | |
| $1.9B | 0.7x | 5.6x | |
| $1.8B | 0.2x | 5.7x | |
| $1.7B | 1.5x | 11.2x | |
| $1.7B | 6.8x | 20.7x | |
| $1.4B | 2.3x | 11.9x | |
| $1.4B | 1.5x | 8.4x | |
| $1.3B | 2.5x | n/a | |
| $1.3B | 1.3x | 12.3x | |
| $1.3B | n/a | n/a | |
| $1.2B | 1.5x | 6.7x | |
| $978M | 2.4x | 34.6x | |
| $972M | 0.6x | 5.9x | |
| $875M | 0.5x | 13.0x | |
| $723M | n/a | n/a | |
| $664M | 0.6x | 4.6x | |
| $637M | 1.1x | 8.2x | |
| $616M | 1.4x | 6.8x | |
| $581M | 0.5x | n/a | |
| $568M | n/a | n/a | |
| $539M | 1.4x | 9.4x | |
| $519M | 1.0x | 6.2x | |
| $513M | 0.2x | 16.5x | |
| $465M | 1.9x | 12.4x | |
| $425M | 9.0x | 29.3x | |
| $408M | 0.3x | 4.3x | |
| $390M | 0.6x | 5.4x | |
| $348M | 1.6x | 9.0x | |
| $325M | 0.6x | 4.5x | |
| $317M | 0.6x | 7.1x | |
| $313M | n/a | n/a | |
| $313M | 0.2x | 2.9x | |
| $313M | 0.6x | 2.1x | |
| $279M | 0.6x | 6.0x | |
| $260M | n/a | n/a | |
| $246M | 6.8x | -7.3x | |
| $227M | n/a | n/a | |
| $204M | n/a | n/a | |
| $169M | n/a | n/a | |
| $165M | 322.4x | -339.9x | |
| $159M | 2.4x | -3.9x | |
| $152M | 0.3x | 4.0x | |
| $150M | 0.6x | 3.9x | |
| $140M | 10.3x | -4.9x | |
| $134M | n/a | n/a | |
| $134M | 1.2x | 6.5x | |
| $117M | 5.9x | 17.9x | |
| $101M | n/a | n/a | |
| $100M | n/a | n/a | |
| $88.0M | n/a | n/a | |
| $83.1M | 583.8x | -14.3x | |
| $69.7M | n/a | n/a | |
| $69.3M | 0.6x | 9.6x | |
| $68.6M | 32.9x | -2.0x | |
| $64.8M | 0.7x | 3.7x | |
| $59.4M | n/a | n/a | |
| $47.1M | 0.6x | 4.7x | |
| $41.9M | n/a | n/a | |
| $40.0M | n/a | n/a | |
| $38.7M | 2.3x | 14.5x | |
| $38.4M | n/a | n/a | |
| $34.5M | n/a | n/a | |
| $34.3M | 0.5x | -49.3x | |
| $32.4M | n/a | n/a | |
| $31.2M | 0.4x | 8.4x | |
| $30.1M | 1.4x | 27.4x | |
| $26.6M | n/a | n/a | |
| $26.3M | 2.0x | 36.6x | |
| $25.7M | n/a | n/a | |
| $25.3M | n/a | n/a | |
| $25.0M | n/a | n/a | |
| $23.1M | 50.2x | -1.9x | |
| $20.4M | 2.0x | -9.9x | |
| $20.1M | n/a | n/a | |
| $19.8M | n/a | n/a | |
| $16.1M | n/a | n/a | |
| $15.8M | 4.1x | -2.4x | |
| $15.0M | 2.5x | -1261.7x | |
| $13.6M | n/a | n/a | |
| $12.4M | n/a | n/a | |
| $12.4M | 1.3x | -4.0x | |
| $9.9M | n/a | n/a | |
| $7.4M | 26.1x | -11.0x | |
| $7.1M | n/a | n/a | |
| $6.8M | n/a | n/a | |
| $6.2M | n/a | n/a | |
| $6.1M | n/a | n/a | |
| $5.5M | n/a | n/a | |
| $4.3M | n/a | n/a | |
| $4.1M | n/a | n/a | |
| $4.0M | n/a | n/a | |
| $3.4M | n/a | n/a | |
| $3.3M | n/a | n/a | |
| $1.5M | n/a | n/a | |
| $1.4M | n/a | n/a | |
| $1.3M | n/a | n/a | |
| $1.1M | n/a | n/a | |
| $0.9M | n/a | n/a | |
| $0.8M | n/a | n/a | |
| $0.2M | n/a | n/a | |
| -$1.6M | -15.0x | 0.4x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Chemicals